Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Receivables (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Receivables for 15 consecutive years, with $25.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Receivables rose 29.47% to $25.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $25.9 million, a 29.47% increase, with the full-year FY2024 number at $24.5 million, up 49.12% from a year prior.
  • Receivables was $25.9 million for Q3 2025 at Gyre Therapeutics, up from $24.9 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $25.9 million in Q3 2025 to a low of $564000.0 in Q1 2022.
  • A 5-year average of $12.2 million and a median of $15.2 million in 2023 define the central range for Receivables.
  • Peak YoY movement for Receivables: plummeted 45.13% in 2021, then surged 842.57% in 2022.
  • Gyre Therapeutics' Receivables stood at $1.8 million in 2021, then soared by 842.57% to $17.1 million in 2022, then fell by 11.51% to $15.2 million in 2023, then skyrocketed by 61.91% to $24.5 million in 2024, then grew by 5.41% to $25.9 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Receivables are $25.9 million (Q3 2025), $24.9 million (Q2 2025), and $22.5 million (Q1 2025).